Last Updated on June 7, 2024 by The Health Master
Medical Device recall
The U.S. Food and Drug Administration (USFDA) has escalated the seriousness classification of the medical device recall on Hologic’s BioZorb Marker, a device implanted in breast tissue during certain procedures.
This action underscores the importance of heightened vigilance by both doctors and patients to identify and address potential side effects.
USFDA Urges Increased Monitoring for BioZorb Marker
While the March 2024 this medical device recall initiated by Hologic wasn’t a product removal but a correction, the USFDA now classifies it as “most serious.”
This emphasizes the potential for complications associated with the BioZorb Marker.
The BioZorb Marker is typically implanted before procedures like radiation therapy for breast cancer.
Its function is to mark the location of lumpectomies or other tissue removals, aiding in future examinations.
However, the USFDA has received concerning reports of:
- Pain
- Infection
- Other complications arising from patients feeling the medical device within the breast tissue
Patient Reporting and Doctor Monitoring Crucial
The USFDA emphasizes the importance of both patients and doctors being proactive in monitoring for side effects.
Here’s a breakdown of the key takeaways:
Patients:
If you have received a BioZorb Marker placement, be particularly attentive to any changes or discomfort in the breast area. Report any pain, infection signs (redness, swelling), or other concerns to your doctor promptly.
Doctors:
The USFDA urges healthcare providers to actively monitor patients who have received BioZorb Markers.
This includes scheduling regular check-ups to assess for potential complications and ensuring patients are aware of the reporting process for any side effects.
Early detection and intervention are crucial for minimizing risks associated with the BioZorb Marker.
By working together, doctors and patients can ensure optimal post-procedure care and successful outcomes.
Current Statistics and Previous Warnings
As of now, the USFDA has received 71 reports of injuries related to the BioZorb Marker, with no fatalities.
It’s important to note that the USFDA previously issued a warning in February 2024 to both patients and healthcare providers regarding the potential for serious complications with the medical device.
This heightened classification by the USFDA serves as a reminder of the importance of ongoing vigilance in medical device safety.
By prioritizing open communication between patients and doctors, we can work towards minimizing risks and ensuring the best possible outcomes for breast cancer patients.
Disclaimer: This article contains information derived from the source mentioned below. Our team utilized an AI language model to rewrite and present the news or article in a unique format.
Procedure to obtain license for manufacturing of Medical Devices
Procedure for registration of Medical Devices: CDSCO
Registration for sale of Medical Devices: Procedure and conditions
Latest Notifications: Medical Devices
Classifications of Medical Devices under the provisions of MDR 2017
Notified Bodies for Medical Devices
Updated list of Notified Bodies for Medical Devices
Updated list of Medical Device Testing Laboratories (MDTLs)
Forms: All types of Medical Devices
Schedules: All types of Medical Devices
FAQs on Medical Devices Rules, 2017
National Medical Devices Policy 2023
Medical Device recall: USFDA classifies recall of this Scientific device as ‘most serious’
Medical Device recall: USFDA classifies recall of this Medical Device as most serious
Medical Device recall: Philips Resolves dispute with USFDA
Medical Device recall: USFDA Classifies this Respiratory Mask Recall as Most Serious
Medical Device recall: Sub-Acute Care Ventilators recalled due to this reason
Medical Device recall: USFDA identifies recall of this Medical Device as most serious
Gujarat FDCA Revokes Licenses of 7 Drug Testing Laboratories
DCGI: Withdraw Cancer drug ‘Olaparib’ for these treatments
USFDA approval granted for Asthma Treatment Drug
USFDA inspection concluded at Solara Pharma without any observations
NPPA revised Ceiling price of 1 scheduled formulation: May 2024
FSSAI: Food Labelling and Display – Chapter-6
Indian Regulators Crack Down on Unapproved Antibiotics to Fight Misuse
CDSCO Committee to Revise Rule 64 for drug sales in India
One Nation-One Pharmacist Registration to Boost Recognition of Pharmacy Professionals
For informative videos by The Health Master, click on the below YouTube icon:
For informative videos on Medical Store / Pharmacy, click on the below YouTube icon:
For informative videos on the news regarding Pharma / Medical Devices / Cosmetics / Homoeopathy etc., click on the below YouTube icon:
For informative videos on consumer awareness, click on the below YouTube icon:
